Amgen Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Capital-Expenditures" stands at 1.59 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Amgen Inc's third quarter result of 0.436 Billion USD for the item "Capital Expenditures" represents an increase of 18.16 percent compared to it's second quarter result.
Also, Amgen Inc's third quarter result of 0.436 Billion USD for the item "Capital Expenditures" represents an increase of 69.65 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Amgen Inc's third quarter result of 1.59 Billion USD for the item "Capital Expenditures" represents an increase of 12.71 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 62.94 percent compared to the value the year prior.
The 1 year change in percent is 62.94.
The 3 year change in percent is 79.73.
The 5 year change in percent is 154.74.
The 10 year change in percent is 102.94.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Capital Expenditures | 905,699,262,464.00 |
![]() | Johnson & Johnson - Capital Expenditures | 486,508,953,600.00 |
![]() | AbbVie Inc - Capital Expenditures | 399,570,305,024.00 |
![]() | Roche Holding AG - Capital Expenditures | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Capital Expenditures | 280,205,508,085.11 |